European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi‐institutional study

Abstract

The performance of the risk calculators in the present cohort shows that the ERSPC-RC is a superior tool in the prediction of PCa; however the performance of the ERSPC-RC in this population does not yet warrant its use in clinical practice. The incorporation of the PHI score into the ERSPC-PHI risk calculator allowed each patient's risk to be more accurately quantified. Individual patient risk calculation using the ERSPC-PHI risk calculator can be undertaken in order to allow a systematic approach to patient risk stratification and to aid in the diagnosis of PCa.

Repeat prostate‐specific antigen (PSA) test before prostate biopsy: a 20% decrease in PSA values is associated with a reduced risk of cancer and particularly of high‐grade cancer

“…Moreover, we included in our present analysis patients with a PSA level >10 ng/mL, which were excluded by the previous analysis and we used the same biopsy template (12 cores) in the entire cohort. According to our present results, PSA level changes should be considered when evaluating patients at risk of prostate cancer and these findings may also have an impact on the available prostate cancer risk calculators , which include a single PSA value and do not consider PSA variations. Prostate cancer risk was as high as 53% in patients with a stable PSA, whilst patients with a decrease in PSA levels of ≥20% had a 33% risk of prostate cancer.…”

External Evaluation of a Novel Prostate Cancer Risk Calculator (ProstateCheck) Based on Data from the Swiss Arm of the ERSPC

“…The updated version of the SWOP RC including the Prostate Health Index (PHI) has recently been shown to be superior to the conventional SWOP-RC in an independent validation study. 30 …”

Clarifying the PSA grey zone: The management of patients with a borderline PSA

“…In validation studies, the ERSPC calculator has consistently outperformed the PCPT 2.0 calculator, both for detecting prostate cancer in general and also for identifying clinically significant cancer, [41][42][43][44] thus, the ERSPC calculator favourably minimises the number of unnecessary biopsies.…”